ULTRA-V: Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)
Categories (click each to see list of all clinical trials associated with that category): Lymphoma/Chronic lymphocytic leukemia (CLL)
Current Status: Open to accrual
Phase: II
Principal Investigator: Bociek, R Gregory
Contact Information:
Susan Blumel, RN
402-559-9183
sblumel@unmc.edu
Eligibility: https://clinicaltrials.gov/ct2/show/NCT03801525?cond=NCT03801525&draw=2&rank=1#eligibility
Summary
Primary Outcome Measures: 1) Overall Response Rate [Time Frame: Up to 12 months] Objective response in subjects treated with ublituximab + umbralisib + venetoclax; Secondary Outcomes Measures: 1) Adverse Events That Are Related to Treatment [Time Frame: 6 months of therapy] Number of Participants With Treatment-Related Adverse Event and any potential abnormal laboratory results